中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.022 seconds)

    CELL THERAPY FOR LIMITING OVERZEALOUS INFLAMMATORY REACTIONS IN TISSUE HEALING
    1.
    发明申请
    CELL THERAPY FOR LIMITING OVERZEALOUS INFLAMMATORY REACTIONS IN TISSUE HEALING 有权
    用于限制组织治疗中的过度炎症反应的细胞疗法

    公开(公告)号：US20110178502A1

    公开(公告)日：2011-07-21

    申请号：US13031431

    申请日：2011-02-21

    Applicant: Mark C. Poznansky ,  Nicolas A.F. Chronos

    Inventor： Mark C. Poznansky ,  Nicolas A.F. Chronos

    IPC: A61M5/142 ,  A61K35/28 ,  A61K9/00 ,  A61P29/00 ,  A61P17/02 ,  A61M5/00

    CPC classification number: A61L31/005 ,  A61K35/17 ,  A61L15/40 ,  A61L27/3804 ,  A61L27/3839

    Abstract: Cells of the B cell lineage including pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and some mature B cells, and/or cells of the T cell lineage, especially those with helper or regulatory function, most preferably autologous to the recipient, can be transplanted into damaged tissue to enhance recovery following injury. In a preferred embodiment, the cells are selected based on those cells which appear at the site of injury a few days after injury, such as macrophages, lymphocytes, which accelerate clean up and repair of the injured site and to mitigate the overzealous inflammatory response, presumably by inhibiting the inflammatory cells such as neutrophils and signals released thereby immediately following injury.

    Abstract translation: B细胞系的细胞包括前B细胞，前B细胞，前B细胞，未成熟B细胞和一些成熟B细胞，和/或T细胞谱系细胞，和/或T细胞谱系的细胞，特别是那些具有辅助或调节 功能，最优选自体接受者，可以移植到受损组织中以增强损伤后的恢复。 在优选的实施方案中，细胞是基于出现在损伤后几天的损伤部位的细胞，例如巨噬细胞，淋巴细胞，其加速对受伤部位的清理和修复并减轻过度炎症反应， 大概是通过抑制炎性细胞如嗜中性粒细胞和由此而迅速释放的信号。

    Cell therapy for limiting overzealous inflammatory reactions in tissue healing
    3.
    发明授权
    Cell therapy for limiting overzealous inflammatory reactions in tissue healing 有权
    细胞疗法限制组织愈合过程中的过度炎症反应

    公开(公告)号：US09220813B2

    公开(公告)日：2015-12-29

    申请号：US13031431

    申请日：2011-02-21

    Applicant: Mark C. Poznansky ,  Nicolas A. F. Chronos

    Inventor： Mark C. Poznansky ,  Nicolas A. F. Chronos

    IPC: C12N5/0781 ,  A61L31/00 ,  A61K35/17 ,  A61L15/40 ,  A61L27/38

    CPC classification number: A61L31/005 ,  A61K35/17 ,  A61L15/40 ,  A61L27/3804 ,  A61L27/3839

    Abstract: Cells of the B cell lineage including pre-pro-B cells, pro-B cells, pre-B cells, immature B cells, and some mature B cells, and/or cells of the T cell lineage, especially those with helper or regulatory function, most preferably autologous to the recipient, can be transplanted into damaged tissue to enhance recovery following injury. In a preferred embodiment, the cells are selected based on those cells which appear at the site of injury a few days after injury, such as macrophages, lymphocytes, which accelerate clean up and repair of the injured site and to mitigate the overzealous inflammatory response, presumably by inhibiting the inflammatory cells such as neutrophils and signals released thereby immediately following injury.

    Abstract translation: B细胞系的细胞包括前B细胞，前B细胞，前B细胞，未成熟B细胞和一些成熟B细胞，和/或T细胞谱系细胞，和/或T细胞谱系的细胞，特别是那些具有辅助或调节 功能，最优选自体接受者，可以移植到受损组织中以增强损伤后的恢复。 在优选的实施方案中，细胞是基于出现在损伤后几天的损伤部位的细胞，例如巨噬细胞，淋巴细胞，其加速对受伤部位的清理和修复并减轻过度炎症反应， 大概是通过抑制炎性细胞如嗜中性粒细胞和由此而迅速释放的信号。

    Fugetactic proteins, compositions and methods of use
    4.
    发明授权
    Fugetactic proteins, compositions and methods of use 失效
    蛋白质组合物，组合物和使用方法

    公开(公告)号：US07745578B2

    公开(公告)日：2010-06-29

    申请号：US10563726

    申请日：2004-07-07

    Applicant: Mark C. Poznansky ,  Dahlia Doughty

    Inventor： Mark C. Poznansky ,  Dahlia Doughty

    IPC: C07K7/00 ,  C07K14/00 ,  A61K38/00

    CPC classification number: A61K38/1709 ,  A61K35/26 ,  A61K38/17 ,  A61K47/646 ,  C07K14/47 ,  G01N33/5029 ,  G01N33/505

    Abstract: This invention relates to compositions and methods that modulate the movement of cells with migratory capacity. More specifically, the invention relates to compositions and methods for promoting migratory movement, fugetaxis, of cells from a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to promote migratory cell movement away from specific sites in a subject. Specific sites include sites of inflammation, infection, an autoimmune reaction, a tumor and a transplanted organ or tissue.

    Abstract translation: 本发明涉及调节具有迁移能力的细胞运动的组合物和方法。 更具体地，本发明涉及用于促进来自受试者中特定部位的细胞的迁移运动，fugetaxis的组合物和方法。 前述内容尤其适用于治疗特征在于需要促进迁移性细胞移动远离受试者的特定部位的病症。 特定部位包括炎症，感染，自身免疫反应，肿瘤和移植的器官或组织的部位。

    CAR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS
    8.
    发明申请
    CAR RECEPTOR AS A MEDIATOR OF MIGRATORY CELL CHEMOTAXIS AND/OR CHEMOKINESIS 审中-公开
    CAR受体作为转染细胞化学和/或化学反应的介质

    公开(公告)号：US20120329153A1

    公开(公告)日：2012-12-27

    申请号：US13118511

    申请日：2011-05-30

    Applicant: Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    Inventor： Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    IPC: C12N5/0789 ,  C12N5/077

    CPC classification number: A61L27/3821 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/59 ,  A61K38/195 ,  A61K38/2006 ,  A61K45/06 ,  A61L27/3804 ,  A61L27/3847 ,  A61K2300/00

    Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating io hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.

    Abstract translation: 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮，内皮或间质来源的CaR受体表达细胞的运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源或排斥的运动。 本发明还涉及用于操作io血型祖细胞和相关产品的方法。 特别地，本发明包括使用CaR受体相关组合物来增强造血祖细胞的动员，提高靶向细胞到骨髓的效率和/或调节造血祖细胞功能的方法和产品。

    CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
    9.
    发明授权
    CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis 有权
    CaR受体作为迁移性细胞趋化性和/或趋化因子的介质

    公开(公告)号：US07951364B2

    公开(公告)日：2011-05-31

    申请号：US11429902

    申请日：2006-05-08

    Applicant: Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    Inventor： Mark C. Poznansky ,  Edward M. Brown ,  David T. Scadden ,  Ivona T. Olszak

    IPC: A01N63/00

    CPC classification number: A61L27/3821 ,  A61K31/00 ,  A61K31/137 ,  A61K31/138 ,  A61K31/59 ,  A61K38/195 ,  A61K38/2006 ,  A61K45/06 ,  A61L27/3804 ,  A61L27/3847 ,  A61K2300/00

    Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating hematopoeitic progenitor cells and related products. In particular the invention includes methods and products for using CaR receptor-related compositions to enhance mobilization of hematopoietic progenitor cells, to improve the efficiency of targeting cells to the bone marrow, and/or to modulate hematopoietic progenitor cell function.

    Abstract translation: 本发明涉及用迁移能力调节真核细胞运动的方法和组合物。 更具体地，本发明涉及用于调节受试者的特定部位中造血，神经，上皮，内皮或间质来源的CaR受体表达细胞的运动的方法和组合物。 前述内容尤其可用于治疗特征在于需要调节与受试者中特定部位相关的迁移细胞运动的病症。 特定部位包括炎症部位和迁移细胞运动的调节是远离药剂来源或排斥的运动。 本发明还涉及操纵造血祖细胞和相关产品的方法。 特别地，本发明包括使用CaR受体相关组合物来增强造血祖细胞的动员，提高靶向细胞到骨髓的效率和/或调节造血祖细胞功能的方法和产品。

Patent Agency Ranking